Lista de obras -

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

scientific article published on 18 February 2020

Anti-CD37 antibodies for chronic lymphocytic leukemia

artículo científico publicado en 2014

Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia

artículo científico publicado en 2016

BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies ⬇️

artículo científico publicado el 25 de abril de 2013

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment

artículo científico publicado en 2011

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

artículo científico publicado en 2016

Current and emerging treatments for chronic lymphocytic leukaemia

artículo científico publicado en 2009

Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

artículo científico publicado en 2009

Current treatment options in prolymphocytic leukemia.

artículo científico publicado en 2007

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

scientific article published on 06 June 2020

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells

artículo científico publicado en 2006

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

scientific article published on 19 April 2020

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors

artículo científico publicado en 2019

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.

artículo científico publicado en 2019

Emerging antibody-drug conjugates for treating lymphoid malignancies

artículo científico

Emerging immunological drugs for chronic lymphocytic leukemia

artículo científico

High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement

scientific article published on 01 August 2006

Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates

artículo científico publicado en 2016

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

scientific article published on 22 July 2018

Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia

artículo científico publicado en 2017

Older and new purine nucleoside analogs for patients with acute leukemias ⬇️

artículo científico publicado el 6 de abril de 2013

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development

artículo científico publicado en 2017

Potential breakthroughs with investigational drugs for hairy cell leukemia

artículo científico

Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.

artículo científico publicado en 2014

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

artículo científico publicado en 2018

Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias

artículo científico publicado en 2012

Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

artículo científico publicado en 2015

Richter's syndrome in the brain first manifested as an ischaemic stroke

artículo científico publicado en 2004

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia

artículo científico publicado en 2010

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

artículo científico publicado en 2015

TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies

artículo científico publicado en 2009

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

scientific article published on 09 September 2020

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies

artículo científico publicado en 2008

Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases

artículo científico publicado en 2012

Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic AgentsIn Vitro

scholarly article in Journal of Chemistry, 2015

Lista de obras de

A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

Anti-CD37 antibodies for chronic lymphocytic leukemia

Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia

BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies ⬇️

Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs in conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment

Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.

Current and emerging treatments for chronic lymphocytic leukaemia

Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

Current treatment options in prolymphocytic leukemia.

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells

Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin‑dependent kinase inhibitors

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.

Emerging antibody-drug conjugates for treating lymphoid malignancies

Emerging immunological drugs for chronic lymphocytic leukemia

High activity of rituximab combined with cladribine and cyclophosphamide in a patient with pulmonary lymphomatoid granulomatosis and bone marrow involvement

Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates

Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases

Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia

Older and new purine nucleoside analogs for patients with acute leukemias ⬇️

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development

Potential breakthroughs with investigational drugs for hairy cell leukemia

Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.

Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.

Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias

Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

Richter's syndrome in the brain first manifested as an ischaemic stroke

Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.

TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients

The role of non-steroidal anti-inflammatory drugs in the risk of development and treatment of hematologic malignancies

Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases

Towards the Application of Atorvastatin to Intensify Proapoptotic Potential of Conventional Antileukemic AgentsIn Vitro